Clinical Data's Vital Diagnostics Division to Exhibit at MEDICA 2006
Business Editors/Healthcare Editors
MEDICA 2006 Trade Show and Congress
NEWTON, Mass.--(BUSINESS WIRE)--Nov. 10, 2006--Clinical Data, Inc. (NASDAQ: CLDA) today announced that its Vital Diagnostics(TM) division will be hosting booth A60 in Hall 3 at the MEDICA 2006 Trade Show and Congress to be held from November 15-18 at the Dusseldorf Trade Fair Centre in Dusseldorf, Germany. For the first time, Vital Scientific NV and Electa Lab s.r.l. will be exhibiting at the same booth.
Since January 2006, Clinical Data's Vital Diagnostics division has consolidated the operations of Vital Scientific NV, Electa Lab s.r.l. and Clinical Data Sales & Service Inc. Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the hospital, physician office and small to medium sized laboratory segment. At Medica, Vital Diagnostics will be present with its full staff, and the team is exhibiting its full line of products supported by our Marketing concept: "Three Sizes One Chemistry," including:
-- Selectra, the best known and most popular family of analyzers
-- Vitalab Dry ISE (dry electrode ISE technology for Junior, E and XL series)
-- Vitalab Reagent Line
-- Turbi-Quick and Lumy Electa Lab's ESR product line
Emile Hugen, Managing Director of Vital Scientific NV, said, "Maintaining a corporate presence at MEDICA is important to our international sales effort and traditionally has generated key leads, and we look forward to again participating along with the several thousand other exhibitors expected at MEDICA 2006. We also excited to use this venue to introduce some of our latest products, show new partners our reliable line of existing products and to further our position as a leader in our sector."
Drew Fromkin, President and CEO of Clinical Data, said "We are very excited to have our Vital Diagnostics division, and in particular the Vital Scientific and Electalab groups, present at MEDICA 2006 once again. It is a wonderful venue for us to meet with our alliance partners and both longstanding and new clients as well as explore emerging opportunities with prospective clients and partners. I personally look forward to meeting with so many great companies."
Further information on the MEDICA conference is available at http://www.medica.de/
About Vital Diagnostics
Vital Diagnostics serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide. With a focus on the physician's office, hospital and small-to-medium sized laboratory segments and customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States.
About Clinical Data, Inc.
Clinical Data, Inc., a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM); Cogenics(TM); and Vital Diagnostics(TM). The Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc., Icoria, Inc., and Genome Express SA to provide a comprehensive range of molecular biology and pharmacogenomics services to pharmaceutical, biotech, academic, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. PGxHealth builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals, Icoria, and Genome Express in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth develops, validates and commercializes novel Therapeutic Diagnostics(TM), in some instances in combination with new and existing therapeutics, to improve patient care. In addition, PGxHealth has a therapeutic drug candidate, vilazodone, currently in late stage clinical trials for the treatment of depression. Clinical Data is headquartered in Newton, Mass. with operations in Texas, Connecticut, North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q. Internet Website: www.clda.com
For Clinical Data, Inc.
John Quirk, 1-646-536-7029
Janine McCargo, 1-646-536-7033